Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

AZD6094

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
BACKGROUND Preclinical data suggest that EGFR tyrosine kinase inhibitors (TKIs) plus MET TKIs are a possible treatment for EGFR… Expand
Is this relevant?
2019
2019
Purpose: Aberrant activation of MET (hepatocyte growth factor receptor) signaling is implicated in the tumorigenesis of human… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Review
2018
Review
2018
First generation or second generation EGFR tyrosine kinase inhibitors are currently the standard of care for the first-line… Expand
Is this relevant?
Highly Cited
2017
Highly Cited
2017
Purpose Patients with advanced papillary renal cell carcinoma (PRCC) have limited therapeutic options. PRCC may involve… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
2016
2016
Lung cancer is the most common cause of cancer death globally with a significant, unmet need for more efficacious treatments. The… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2015
2015
2509 Background: AZD9291 is an irreversible, mutant-selective EGFR tyrosine kinase inhibitor (TKI) developed to have potency… Expand
  • table 1
Is this relevant?
2015
2015
Purpose: Papillary renal cell carcinoma (PRCC) is the second most common cancer of the kidney and carries a poor prognosis for… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 6
Is this relevant?
2015
2015
487 Background: Met is a receptor tyrosine kinase that is deregulated across multiple cancer types, leading to uncontrolled tumor… Expand
Is this relevant?
2015
2015
Background: Volitinib is a selective oral small molecule inhibitor of cMet kinase, which has demonstrated potent in vivo… Expand
Is this relevant?
2015
2015
Aberrant receptor tyrosine kinase (RTK) signaling is a well-documented driver of disease onset and progression across myriad… Expand
Is this relevant?